Format

Send to

Choose Destination
Pharm Dev Technol. 2018 Apr;23(4):343-350. doi: 10.1080/10837450.2017.1290107. Epub 2017 Feb 20.

Development and characterization of poly(lactic-co-glycolic) acid nanoparticles loaded with copaiba oleoresin.

Author information

1
a Department of Pharmaceutics , Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.
2
b Research Program in Cellular Biology and Development, Institute of Biomedical Sciences, Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.
3
c School of Pharmacy, Trinity College, University of Dublin , Dublin , Ireland.

Abstract

Copaiba oleoresin (CPO), obtained from Copaifera landgroffii, is described as active to a large number of diseases and more recently in the endometriosis treatment. In this work, poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing CPO were obtained using the design of experiments (DOE) as a tool to optimize the production process. The nanoparticles optimized by means of DOE presented an activity in relation to the cellular viability of endometrial cells. The DOE showed that higher amounts of CPO combined with higher surfactant concentrations resulted in better encapsulation efficiency and size distribution along with good stability after freeze drying. The encapsulation efficiency was over 80% for all produced nanoparticles, which also presented sizes below 300 nm and spherical shape. A decrease in viability of endometrial stromal cells from ectopic endometrium of patients with endometriosis and from eutopic endometriotic lesions was demonstrated after 48 h of incubation with the CPO nanoparticles. The nanoparticles without CPO were not able to alter the cell viability of the same cells, indicating that this material was not cytotoxic to the tested cells and suggesting that the effect was specific to CPO. The results indicate that the use of CPO nanoparticles may represent a promising alternative for the treatment of endometriosis.

KEYWORDS:

Copaiba oleoresin; Copaifera landgroffii; PLGA; design of experiments; endometriosis; nanoparticles

PMID:
28145793
DOI:
10.1080/10837450.2017.1290107
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center